Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus for Breast Cancer at 2025 Symposium
TL;DR
Oncotelic's novel Sapu003 formulation offers a potential competitive advantage by overcoming limitations of existing mTOR inhibitors like Afinitor through improved bioavailability and tumor penetration.
Sapu003 is an intravenous formulation of everolimus developed through nanomedicine technology to address poor bioavailability and restricted tumor penetration issues of oral mTOR inhibitors.
This innovative cancer therapy could significantly improve treatment outcomes for HR⁺/HER2⁻ metastatic breast cancer patients, advancing the fight against high-unmet-need cancers.
Oncotelic will present three abstracts on its novel IV Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, showcasing clinical data from its ongoing Phase 1 trial.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that three abstracts featuring its investigational intravenous Deciparticle everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12 in San Antonio, Texas. The acceptance of multiple abstracts indicates significant scientific interest in this novel formulation, which represents a potential advancement in breast cancer treatment.
The investigational drug Sapu003, developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—is a novel intravenous formulation of everolimus specifically designed to overcome limitations of oral mTOR inhibitors such as Afinitor. Current oral formulations face challenges including poor bioavailability and restricted tumor penetration, which can limit their effectiveness in treating metastatic breast cancer. The abstracts scheduled for presentation will collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer patients.
This development is particularly important because HR⁺/HER2⁻ metastatic breast cancer represents a significant portion of breast cancer cases, and improved treatment options are continually needed. The intravenous formulation approach could potentially enhance drug delivery to tumor sites, improving therapeutic outcomes for patients who may not respond adequately to current oral therapies. The pharmacokinetic data to be presented will provide crucial insights into how the drug behaves in the body and its potential advantages over existing treatments.
The acceptance of these abstracts at a prestigious medical symposium like the San Antonio Breast Cancer Symposium underscores the scientific community's interest in novel approaches to cancer treatment. For investors and stakeholders, additional information about Oncotelic Therapeutics is available in the company's newsroom at https://ibn.fm/OTLC. The full press release containing detailed information about the abstract acceptances can be viewed at https://ibn.fm/Ut6V8.
As breast cancer remains one of the most common cancers affecting women worldwide, advancements in treatment formulations that address existing limitations could have substantial impact on patient care and outcomes. The Phase 1 trial data, when available, will be critical in determining whether this intravenous formulation represents a meaningful improvement over current standard treatments for metastatic breast cancer patients.
Curated from InvestorBrandNetwork (IBN)
